Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 10, 2020 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and...
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
August 25, 2020 09:15 ET
|
Capricor Therapeutics
– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 – – The Study Leverages Capricor’s Lead Asset,...
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 06, 2020 16:01 ET
|
Capricor Therapeutics
Exosome Platform for COVID-19-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies--Preclinical Data Shows Positive Antibody Response- CAP-1002 for COVID-19-Expanded...
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
July 30, 2020 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, July 30, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based...
Capricor to Participate in BIO Digital International Convention
June 04, 2020 09:15 ET
|
Capricor Therapeutics
Management to Host One-on-One Partnering Meetings Conference June 8-12, 2020 LOS ANGELES, June 04, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a...
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
May 26, 2020 09:25 ET
|
Capricor Therapeutics
LOS ANGELES, May 26, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological...
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 16:01 ET
|
Capricor Therapeutics
Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0...
Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
May 13, 2020 16:30 ET
|
Capricor Therapeutics
LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological...
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
May 13, 2020 07:00 ET
|
Capricor Therapeutics
-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that Correlates Stabilization...
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
April 29, 2020 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological...